Amgen Inc. $AMGN Shares Sold by Orion Porfolio Solutions LLC

Orion Porfolio Solutions LLC lowered its position in Amgen Inc. (NASDAQ:AMGN) by 4.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 29,462 shares of the medical research company’s stock after selling 1,488 shares during the period. Orion Porfolio Solutions LLC’s holdings in Amgen were worth $8,314,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of AMGN. IFG Advisory LLC increased its stake in shares of Amgen by 1.2% during the third quarter. IFG Advisory LLC now owns 9,289 shares of the medical research company’s stock worth $2,621,000 after purchasing an additional 106 shares in the last quarter. Viawealth LLC lifted its stake in Amgen by 0.4% in the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after buying an additional 30 shares in the last quarter. Cambria Investment Management L.P. purchased a new position in Amgen in the 3rd quarter valued at about $363,000. Dimensional Fund Advisors LP boosted its holdings in Amgen by 5.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,178,590 shares of the medical research company’s stock worth $896,843,000 after buying an additional 154,664 shares during the last quarter. Finally, Insigneo Advisory Services LLC boosted its holdings in Amgen by 3.3% in the 3rd quarter. Insigneo Advisory Services LLC now owns 3,017 shares of the medical research company’s stock worth $851,000 after buying an additional 95 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on AMGN shares. Rothschild & Co Redburn increased their target price on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a report on Wednesday, February 18th. Cantor Fitzgerald lifted their price target on Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Guggenheim increased their price objective on Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Finally, Erste Group Bank upgraded Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $354.17.

Amgen Trading Up 0.5%

Shares of AMGN opened at $369.53 on Friday. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The firm has a market capitalization of $199.20 billion, a P/E ratio of 25.97, a P/E/G ratio of 3.65 and a beta of 0.45. The firm has a 50-day moving average price of $353.26 and a 200 day moving average price of $322.43. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s quarterly revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is 70.84%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent quarter beat revenue and EPS estimates and management issued FY?2026 EPS guidance, which supports the buy thesis and helped lift sentiment. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Positive Sentiment: The board declared a $2.52 quarterly dividend (ex?dividend May 15), reinforcing shareholder returns and supporting income?oriented demand for the stock. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference (Mar 11). The fireside chat with the CFO and rare?disease head could provide more detail on pipeline priorities and capital allocation — a potential catalyst depending on the tone. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Short?interest data reported for early March appears to show no meaningful short position (entries list zeros/NaN), which suggests short sellers are not a large immediate pressure point — note the data may reflect reporting quirks.
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals linking OX40 pathway modulation to malignancies. Losing a late?stage immunology asset is a clear pipeline setback and could reduce upside from future launches. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: Senate Democrats are pressing pharma companies over pricing deals tied to the prior administration, raising the risk of increased political and regulatory scrutiny that could pressure margins or pricing for large biopharma firms including Amgen. Pharma giants pressed by Senate Democrats over Trump pricing deals
• Negative Sentiment: At least one analyst piece has downgraded the stock to a “hold” / advised waiting for a better entry point, signaling some caution on valuation after the recent run. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.